Cargando…

Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report

Hepatocellular carcinoma is rare, but increasing in prevalence in the United States. Recent studies have shown that sorafenib, a multikinase inhibitor, can reduce tumor progression in patients with this cancer. However, complete remission has not been observed. We report a case of a 78-year old pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	So, Brian J, Bekaii-Saab, Tanios, Bloomston, Mark A, Patel, Tushar
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2575202/ https://www.ncbi.nlm.nih.gov/pubmed/18928548 http://dx.doi.org/10.1186/1756-8722-1-18

Ejemplares similares

Frontline therapy for advanced hepatocellular carcinoma: an update
por: Akce, Mehmet, et al.
Publicado: (2022)

New developments in the treatment of metastatic gastric cancer: focus on trastuzumab
por: Rose, Jeffrey S, et al.
Publicado: (2011)

Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements
por: Walden, Daniel, et al.
Publicado: (2022)

Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives
por: Bupathi, Manojkumar, et al.
Publicado: (2016)

A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma
por: Bekaii-Saab, Tanios, et al.
Publicado: (2006)

Response to Drs Von Hoff and Renschler
por: Ahn, Daniel H., et al.
Publicado: (2017)

Update to “Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors”
por: Zhu, Mojun, et al.
Publicado: (2022)

CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer
por: Wu, Christina, et al.
Publicado: (2012)

Management of Venous Thromboembolism in Patients with Advanced Gastrointestinal Cancers: What Is the Role of Novel Oral Anticoagulants?
por: Martin, Ludmila Katherine, et al.
Publicado: (2012)

The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies
por: Ahn, Daniel H., et al.
Publicado: (2017)

Identifying and targeting cancer stem cells in the treatment of gastric cancer
por: Bekaii‐Saab, Tanios, et al.
Publicado: (2017)

Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma
por: Takano, Michitoshi, et al.
Publicado: (2016)

Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma
por: Storandt, Michael H., et al.
Publicado: (2022)

Complete Response to Sorafenib Rechallenge in a Patient with Metastatic Renal Cell Carcinoma
por: Kasahara, Ryo, et al.
Publicado: (2017)

Sorafenib Improves Survival in Metastatic Hepatocellular Carcinoma: A Case Report
por: Nery, Filipe, et al.
Publicado: (2010)

Genetically engineered murine pancreatic cancer models approximate immunophenotypic properties of human patients
por: Mace, Thomas A, et al.
Publicado: (2013)

Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma
por: Ahn, Daniel H., et al.
Publicado: (2018)

Therapeutic Targeting Strategies of Cancer Stem Cells in Gastrointestinal Malignancies
por: Sonbol, Mohamad B., et al.
Publicado: (2019)

Metastatic carcinoma of unknown primary with complete metabolic response following sorafenib-based chemotherapy
por: Usón Junior, Pedro Luiz Serrano, et al.
Publicado: (2019)

Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response
por: Zhang, Yingqiang, et al.
Publicado: (2015)

Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review
por: Kim, Tae Suk, et al.
Publicado: (2017)

Anti-IL-6 and PD-L1 antibody combination therapy reduces tumor progression in murine models of pancreatic cancer
por: Mace, Thomas, et al.
Publicado: (2015)

BMS-911543 inhibits viability of tumor and stromal cells and limits disease progression in genetically engineered mice with pancreatic cancer
por: Mace, Thomas, et al.
Publicado: (2014)

The Enhanced Metastatic Potential of Hepatocellular Carcinoma (HCC) Cells with Sorafenib Resistance
por: Chow, Ariel Ka-Man, et al.
Publicado: (2013)

Exacerbation of Psoriasis with Pustulation by Sorafenib in a Patient with Metastatic Hepatocellular Carcinoma
por: Ohashi, Takenobu, et al.
Publicado: (2019)

Using Naïve Bayesian Analysis to Determine Imaging Characteristics of KRAS Mutations in Metastatic Colon Cancer
por: Pershad, Yash, et al.
Publicado: (2017)

Favorable Response of Metastatic Hepatocellular Carcinoma to Treatment with Trans-arterial Radioembolization Followed by Sorafenib and Nivolumab
por: Adcock, Charles S, et al.
Publicado: (2019)

Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib
por: Liu, Daizhong, et al.
Publicado: (2015)

Hepatocellular Carcinoma Arising in a Non-cirrhotic Liver with Secondary Hemochromatosis
por: Yamauchi, Ryo, et al.
Publicado: (2018)

The effect of apatinib in the treatment of sorafenib resistant metastatic hepatocellular carcinoma: A case report
por: Han, Zonghong, et al.
Publicado: (2018)

Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma
por: Murugesan, Karthikeyan, et al.
Publicado: (2021)

Higher age at diagnosis of hemochromatosis is the strongest predictor of the occurrence of hepatocellular carcinoma in the Swiss hemochromatosis cohort: A prospective longitudinal observational study
por: Nowak, Albina, et al.
Publicado: (2018)

Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes
por: Bekaii-Saab, Tanios S, et al.
Publicado: (2023)

Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma
por: Huang, Song-Fong, et al.
Publicado: (2022)

Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer
por: Chen, Li-Tzong, et al.
Publicado: (2019)

Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib
por: Kermiche-Rahali, Sabrina, et al.
Publicado: (2013)

Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors
por: Ahn, Daniel H., et al.
Publicado: (2015)

Sustained complete response of hepatocellular carcinoma with portal vein tumor thrombus following discontinuation of sorafenib: A case report
por: SHIOZAWA, KAZUE, et al.
Publicado: (2014)

Complete remission in metastatic hepatocellular carcinoma
por: Ben Kridis, Wala, et al.
Publicado: (2023)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_md6tbjkc30iuuom1ef6adiv0mk